As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments.
The appraisal is expected to start in late April 2023 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-June 2023. The deadline for submissions is expected in approximately mid-August 2023.
For information, this was originally terminated guidance TA700.